Tyrosine kinase inhibitor in combination with chemo shows benefit in acute myeloid leukaemia

New cytarabine combinations could overcome toxicities in AML treatment

Paediatric leukaemia treatment regimens lead to improved outcomes in adolescents and young adults

Targeted therapy effective in elderly patients with Philadelphia-positive acute lymphocytic leukaemia

First randomised evidence for benefit from adding a tyrosine kinase inhibitor in acute myeloid leukaemia

Children with rare leukaemia have better-than-expected outcomes after tailored treatment

Chemo-free treatment approach demonstrates positive responses in leukaemia patients

Compound improves survival in aggressive acute myeloid leukaemia with manageable added toxicity in phase III trial

Blocking PD-1 activity could be safe and effective in classical Hodgkin lymphoma

Nivolumab shows early promise in Hodgkin lymphoma

Blinatumomab demonstrates significant clinical activity in residual ALL

New immunotherapy compound effective, safe in ALL patients with minimal residual disease